TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06189638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimicrobial Peptide PL-5 Topical Spray and Placebo
Description: Antimicrobial Peptide PL-5 Topical Spray At about 5 cm vertically above the wound, the investigator sprays antimicrobial peptide PL-5 topical spray on the test wound. The cover area after spraying is a cone with a surface diameter of about 5 cm and area about 20 cm2. One spray dose is about 0.1 ml. The number of drug sprays is determined according to the wound area in the screening period, and the determined dose is applied consistently. During the operation, an effective spray operation is completely ejected with no leakage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimicrobial Peptide PL-5 Topical Spray and Placebo
Description: Antimicrobial Peptide PL-5 Topical Spray At about 5 cm vertically above the wound, the investigator sprays antimicrobial peptide PL-5 topical spray on the test wound. The cover area after spraying is a cone with a surface diameter of about 5 cm and area about 20 cm2. One spray dose is about 0.1 ml. The number of drug sprays is determined according to the wound area in the screening period, and the determined dose is applied consistently. During the operation, an effective spray operation is completely ejected with no leakage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antimicrobial Peptide PL-5 Topical Spray and Placebo
Description: Antimicrobial Peptide PL-5 Topical Spray At about 5 cm vertically above the wound, the investigator sprays antimicrobial peptide PL-5 topical spray on the test wound. The cover area after spraying is a cone with a surface diameter of about 5 cm and area about 20 cm2. One spray dose is about 0.1 ml. The number of drug sprays is determined according to the wound area in the screening period, and the determined dose is applied consistently. During the operation, an effective spray operation is completely ejected with no leakage.
Study: NCT06357325

Intervention type: OTHER
Intervention: a qualitative study.
Description: Before the interview process began, an interview form was created in accordance with the study design. In the study, care was taken to use open-ended general questions that would allow the participant to provide detailed information on the subject and did not require short answers such as short and clear questions, multiple choice questions, and yes-no questions.~For the analysis and reporting phase, an introduction was made in the form of a conversation with the participant before starting the interview, and then the interview was started if the participant was available. During the transcription phase, the questions were asked during the interview in such a way as to allow the participant to express themselves in detail without any direction or comment. The interview was conducted individually by calling each woman by telephone. During the interview, the researcher transcribed the interviewee's sentences exactly as she expressed them.
Study: NCT05468359

Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab
Description: Atezolizumab intravenously, every 3 weeks, Day 1

Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Description: Sorafenib by mouth every 12 hours, Days 1-21

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab intravenously, every 3 weeks, Day 1
Study: NCT06166056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6333
Description: CHF6333 Part I SAD; CHF6333 Part II MD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CHF6333 Placebo
Description: Placebo Part I SAD; Placebo Part II MD.
Study: NCT05242029

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo in a clinical setting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo in a clinical setting.
Study: NCT05468359

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Low-dose cyclophosphamide by mouth once daily, Days 1-21
Study: NCT05762289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust Manipulation (in weight bearing and non weight bearing)
Description: Pain and Range of cervical motion was assessed before and after manipulation in both groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thrust Manipulation (in weight bearing and non weight bearing)
Description: Pain and Range of cervical motion was assessed before and after manipulation in both groups.
Study: NCT06246266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Helfer Skin Tap Technique group
Description: During intramuscular vaccine administration, the muscle will be tapped with the palmar surface of the fingers of the other hand that is not used, with light rhythmic movements, counting for 1-15 seconds. Then, when the muscle is entered with the injection, it will continue to be hit with light rhythmic movements for 1-3 seconds. Thus, the muscle will relax and the fibers around the muscle will be stimulated. Mechanical stimulation given with the Helfer Skin Tap technique during intramuscular vaccine administration will distract the baby's attention.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ShotBlocker Technique group
Description: The protruding but not sharp surface on the ShotBlocker tool will be placed on the baby's skin before intramuscular vaccine administration.~Injection will be applied to the middle part of this vehicle, which has a 'U' appearance. This tool, which does not cause any harm to the skin surface, will provide stimulation to the muscle fibers according to the Gate Control Theory related to pain.
Study: NCT05144126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT radioraphic assessment
Description: CT radioraphic assessment
Study: NCT05163782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New ankle foot orthosis with anterior support
Description: New ankle foot orthosis with anterior support developed by Turbomed
Study: NCT04714619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-103
Description: Patients will receive CB-103 capsules orally (QD) in combination with NSAI therapy (letrozole or anastrozole, continuing prior therapy) also orally once daily, and based on a 28-day treatment cycle.~A run-in phase for safety and tolerability of CB-103 in combination with anastrozole or letrozole will be conducted as an initial step of the phase II trial to confirm the safe dose of CB-103 in combination with NSAI given at standard dose.~Patients will receive treatment until disease progression (as defined by RECIST v.1.1), symptomatic deterioration, unacceptable toxicity, death, consent withdrawal or study termination, whichever occurs first.
Study: NCT05625256

Intervention type: DEVICE
Intervention: SentiCor-300
Description: Continuous blood pressure measurement with the SentiCor-300.
Study: NCT05242029

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: Participants will receive 40mg psilocybin in a clinical setting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive 40mg psilocybin in a clinical setting.
Study: NCT05163782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis with anterior support
Description: Ankle foot orthosis with anterior support from Turbomed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis from competitor 1
Description: Ankle foot orthosis with posterior support from competitor 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis from competitor 2
Description: Ankle foot orthosis with posterior support from competitor 2
Study: NCT04663724

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Based Treatment
Description: A 4-week (8 30-minute sessions) course of computer-based treatment involving viewing pictures of faces while music may play. Participants will receive research treatment twice a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-Based Treatment
Description: A 4-week (8 30-minute sessions) course of computer-based treatment involving viewing pictures of faces while music may play. Participants will receive research treatment twice a week.
Study: NCT05808881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene Hydrochloride Injection
Description: for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone Hydrochloride Injection
Description: for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
Study: NCT06019741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban and aspirin 80
Description: rivaroxaban 2.5 mg twice daily orally added to aspirin 80 mg post coronary bypass surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 80
Description: aspirin 80 mg orally post coronary bypass surgery
Study: NCT04772482

Intervention type: DIAGNOSTIC_TEST
Intervention: Sensitivity Patch Testing
Description: Testing patches will be applied on the upper arms. Para-phenylene diamine (PPD) 1% will be applied on one upper arm. Para-toluenediamine sulfate (PTD), 2-methoxyethyl p-phenylenediamine (ME-PPD), PPD6 and PPD7 will be applied to the other upper arm.
Study: NCT06474728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with an Emollient Containing Postbiotic Saccharomyces and Lactobacillus
Description: Treatment with an Emollient Containing Postbiotic Saccharomyces and Lactobacillus, with the dose of 100g per week,lasting for 12weeks.
Study: NCT05737914

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic thoracic T3 sympathectomy
Description: Interruption of intrathoracic sympathetic neural pathway surgically to treat hyperhidrosis by using video - thoracoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ThoracicT3 radiofrequency ablation
Description: radiofrequency ablation at third thoracic spine it may be a good option for treatment of primary hyperhidrosis.
Study: NCT06182553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory Rib Cage Compression
Description: Expiratory rib cage compression (ERCC) In this study, ERCC is a technique consisting of bilateral manual compression of the lower rib cage (anterolateral region of the chest at the level of the six last ribs) gradually during the expiratory phase of the ventilatory cycle and release from the compression at the end of the expiration.
Study: NCT04665271

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Zemedy App
Description: Digital smart phone app that delivers cognitive-behavioral therapy for IBS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zemedy App
Description: Digital smart phone app that delivers cognitive-behavioral therapy for IBS
Study: NCT06182553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP-ZEEP Maneuver
Description: PEEP-ZEEP maneuver In this study, PEEP-ZEEP maneuver refers to PEEP which stands for positive end-expiratory pressure, and ZEEP which stands for zero end-expiratory pressure. In this maneuver PEEP will be incremented to 15 cmH2O throughout five consecutive respiratory cycles, then immediately after the inspiratory phase of the fifth cycle has been ended ZEEP should be done by abruptly reducing PEEP value to 0 cmH2O. The PEEP-ZEEP maneuver should be performed in two sets, consisting of a total of 10 consecutive breathing cycles. Subsequently, the patient is ventilated according to his/her baseline ventilator parameters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERCC + PEEP-ZEEP maneuver
Description: - The ERCC technique will be applied as mentioned above, then followed by PEEP-ZEEP maneuvers according to the standard steps mentioned before.
Study: NCT06436196

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscope
Description: Use of Video laryngoscope to secure airway

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope
Description: Macintosh or Miller's laryngoscopes used to secure paediatric airways
Study: NCT05147051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meglumine Sodium Succinate
Description: 500 ml of 1.4% solution IV at a rate of at least 4 ml and not more than 10 ml per minute

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ringer's solution, 500 ml IV at a rate of at least 4 ml and not more than 10 ml per minute
Study: NCT04474938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 16mg/kg, QW Cycles 1-2 (28 days/cycle), Q2W Cycles 3-6, and Q4W thereafter for up to 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3mg/m2 of subcutaneous bortezomib on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20mg of dexamethasone on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles
Study: NCT06195943

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise Intervention with use of El-Fit App
Description: Along with wearing their Fitbit daily, subjects will be asked to use El-Fit app to participant in daily exercise as much or a little as they want over the course of the study.
Study: NCT05116995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: rivaroxaban 2.5 mg twice a day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: rivaroxaban 2.5 mg twice a day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 60 mg twice a day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 60 mg twice a day for 7 days
Study: NCT00817973

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cod

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten
Study: NCT06106529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: Oxybutynin 5 mg twice per day for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: Oxybutynin 5 mg twice per day for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine 37.5 mg once daily for 7 days followed by 75 mg once daily for 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine 37.5 mg once daily for 7 days followed by 75 mg once daily for 5 weeks
Study: NCT06014840

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD
Description: Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD
Study: NCT04948853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement Support - Supported Employment
Description: Individual, person-centered intervention designed to help individuals living with mental illnesses obtain and sustain meaningful employment. This is an evidence-based practice for individuals with severe mental illnesses.
Study: NCT06014840

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD
Description: Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD
Study: NCT06301425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Patients in interventional group could choose one of the following treatment protocols and then receive allo-HSCT if they were CR after the second consolidation:~1. . Venetoclax plus azacitidine: azacitidine 75mg/m2/d d1-7; venetoclax 400mg/d, d1-21;~2. . Venetoclax plus CAG: venetoclax 400mg qd d1-14; aclacinomycin 20mg qd d1-4; cytarabine 10mg/m2 q12h subcutaneous injection d1-14; G-CSF 300μg qd d1-14;~3. . Venetoclax plus IA: venetoclax 400mg qd d1-4; idarubicin 10mg qd d1-4; cytarabine 500mg qd d1-4;~4. . Venetoclax plus AA: venetoclax 400mg qd d1-7; aclacinomycin 20mg qd d1-7; cytarabine 100mg/m2 qd d1-7.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Receive allo-HSCT directly without the second consolidation chemotherapy.
Study: NCT06178081

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal Healthy
Description: Non surgical periodontal therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodontal Healthy
Description: Non surgical periodontal therapy
Study: NCT04802811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2150；Placebo
Description: Single dose；SHR2150-dose 1 or Placebo-dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2150；Placebo
Description: Single dose；SHR2150-dose 2 or Placebo-dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2150；Placebo
Description: Single dose；SHR2150-dose 3 or Placebo-dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2150；Placebo
Description: Single dose；SHR2150-dose 4 or Placebo-dose 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2150；Placebo
Description: Single dose；SHR2150-dose 5 or Placebo-dose 5
Study: NCT05718973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: short, animated storytelling video (intervention video)
Description: Participants in the Intervention Arm will view a short, animated storytelling video designed to promote psychological capital.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: short, animated storytelling attention placebo video
Description: The Attention Placebo Control Arm will view an attention placebo control video, unrelated to the outcomes measured in this trial.
Study: NCT05927038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Description: After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of caffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Description: After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of decaffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.
Study: NCT04891016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT combined with toripalimab
Description: Patients received FLOT combined with toripalimab on Day 3 every 3 weeks, for a total of 3 cycles, followed by surgical treatment. Postoperative adjuvant therapy was determined based on pathological results: if a pathological complete response (pCR) was achieved, patients received 2 additional cycles of the neoadjuvant regimen; if pCR was not achieved, patients were given 4 cycles of SOX combined with toripalimab postoperatively.
Study: NCT04914780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education intervention with mobile application for 4 weeks
Study: NCT05999695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-management
Description: The experimental group received the SelfManagement Program for Acute Coronary Syndrome:~the research subjects completed the first data collection within one week of hospitalization. Guide the research subjects to browse this manual and watch the Acute Coronary Self-Care Video, and explain what they do not understand, hoping to stimulate the research subjects to discuss nursing issues, and jointly formulate self-management goals, and This handbook was given to study subjects to take home. Telephone interviews every 2 weeks in the first month after discharge, and then again after two and three months after discharge. Each call is about 10 minutes to track the completion of goals and self-management,including usual medication, regular exercise, balance Food and spiritual support and encouragement, etc.,and clarify any doubts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular care
Description: gular care regular care The nurse implements routine nursing instructions, including disease and treatment profiles,symptom management, and outpatient follow-up. Scan the QRC with your mobile phone or provide the Care Guidance Leaflet for Coronary Artery Disease and Caring for Myocardial Infarction Patients which are all written in text.
Study: NCT05441826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB119
Description: Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.
Study: NCT05999695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular care
Description: gular care regular care The nurse implements routine nursing instructions, including disease and treatment profiles,symptom management, and outpatient follow-up. Scan the QRC with your mobile phone or provide the Care Guidance Leaflet for Coronary Artery Disease and Caring for Myocardial Infarction Patients which are all written in text.
Study: NCT06440473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: Roflumilast 0.3% cream

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Roflumilast 0.3% vehicle cream)
Description: Vehicle (Roflumilast 0.3% vehicle cream)
Study: NCT05720650

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06021314

Intervention type: OTHER
Intervention: Brace
Description: Cheneau type scoliosis brace due to brace indication for adolecant idiopatic scoliosis
Study: NCT05624476

Intervention type: DIAGNOSTIC_TEST
Intervention: mNGS of urine cell-free DNA
Description: Metagenomic sequencing of urine cell-free DNA

Intervention type: DIAGNOSTIC_TEST
Intervention: mNGS of urine cell-free DNA
Description: Metagenomic sequencing of urine cell-free DNA